Results 1 to 10 of about 1,067 (102)

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials

Journal of Infection and Public Health, 2021
Background: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been ...
Manoj Kumar Saurabh, Parvati Patel, Tejas Patel   +2 more
exaly   +3 more sources

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019 [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19).
Ji-Won Kim, Eun Jin Kim, Hyun Hee Kwon, Chi Young Jung, Kyung Chan Kim, Jung-Yoon Choe, Hyo-Lim Hong   +6 more
doaj   +1 more source

COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?

Pharmaceuticals, 2021
The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the ...
Jean Jacques Vanden Eynde
doaj   +1 more source

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Frontiers in Pharmacology, 2021
Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods:
Mario Karolyi, Sara Omid, Erich Pawelka, Bernd Jilma, Thomas Stimpfl, Christian Schoergenhofer, Hermann Laferl, Tamara Seitz, Marianna Traugott, Christoph Wenisch, Alexander Zoufaly   +10 more
doaj   +1 more source

Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report

Frontiers in Pharmacology, 2023
With the improving life expectancy of patients with human immunodeficiency virus (HIV), there is an increasing health concern of potential toxicity and drug interactions of long-term antiretroviral therapies.
Xuechun Mu, Yujiao Duan, Qiuhua Xu, Sa Wang, Guiju Gao, Ning Han, Hongxin Zhao   +6 more
doaj   +1 more source

Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether‐à‐go‐go–Related Gene and Cav1.2

Frontiers in Pharmacology, 2022
Background: Old drugs for new indications in the novel coronavirus disease of 2019 (COVID-19) pandemic have raised concerns regarding cardiotoxicity, especially the development of drug-induced QT prolongation.
Zequn Zheng, Zequn Zheng, Zequn Zheng, Dihui Cai, Dihui Cai, Yin Fu, Yin Fu, Ying Wang, Yongfei Song, Yongfei Song, Jiangfang Lian, Jiangfang Lian   +11 more
doaj   +1 more source

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection

Pharmaceutics, 2021
Most antiretroviral medications for human immunodeficiency virus treatment and prevention require high levels of patient adherence, such that medications need to be administered daily without missing doses.
Irin Tanaudommongkon, Asama Tanaudommongkon, Xiaowei Dong   +2 more
doaj   +1 more source

Aspects of the safe use of medicinal products based on medicinal plant materials in COVID-19

Реальная клиническая практика: данные и доказательства, 2022
According to a number of studies, medicinal plants and drugs based on them can be used as inhibitors of various viral infections, including the SARS-CoV-2 virus at different stages of their manifestation and development.
A. A. Taube
doaj   +1 more source

Use of B‐complex vitamins and olfactory training for treating COVID‐19–related anosmia

Clinical Case Reports, 2021
A 42‐year‐old male patient was diagnosed with coronavirus disease 2019. His symptoms improved 2 weeks after lopinavir therapy (800 mg/day). However, he was subsequently diagnosed with complete anosmia.
Yethindra Vityala, Aliya Kadyrova, Shirin Zhumabaeva, Aizhan Bazarbaeva, Sagynali Mamatov   +4 more
doaj   +1 more source

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Терапевтический архив, 2021
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of ...
Natalia Yu. Pshenichnaya, Elena N. Kareva, Irina A. Leneva, Vilya A. Bulgakova, Irina E. Kravchenko, Irina V. Nikolaeva, Antonina I. Grekova, Antonina P. Ivanova, Larisa V. Puzyreva, Guzel M. Khasanova, Svetlana N. Orlova, Elena P. Tikhonova, Vladimir A. Petrov, Oleg V. Malinin, Natalia V. Kolaeva, Elena V. Volchkova, Nina N. Kanshina, Vladimir P. Chulanov   +17 more
doaj   +1 more source